Last reviewed · How we verify
Esmolol administration
Beta-1 adrenergic receptor antagonist
Beta-1 adrenergic receptor antagonist Used for Hypertension, Tachyarrhythmias.
At a glance
| Generic name | Esmolol administration |
|---|---|
| Also known as | BREVIBLOC 10 mg/ml, Drug by Qilu Pharmaceutical Co, Shandong, China |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Beta blocker |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Esmolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure.
Approved indications
- Hypertension
- Tachyarrhythmias
Common side effects
- Hypotension
- Bradycardia
- Headache
Key clinical trials
- POCUS-Guided Esmolol in Septic Shock: A Pilot RCT (PHASE1, PHASE2)
- Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage (PHASE3)
- Opioids Continue to Play a Primary Role in the Management of Perioperative Pain Due to Opioid-Free Anesthesia in Open Heart Surgery.
- Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery (PHASE4)
- Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke (PHASE3)
- Concomitant Milrinone and Esmolol Treatment in Patients with Acute Myocardial Infarction (PHASE2)
- Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage
- Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |